Literature DB >> 35302318

晨宏 钱, 烈浩 蒋, 世莹 许, 佳峰 王, 卓 谭, 莹 忻, 明华 葛.   

Abstract

（ATC）、，，，。ATC。ATC；B1（）ATC，2021ATC；，1ATC；、γ、。ATC。.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; Clinical treatment; Immunotherapy; Review; Targeted therapy

Year:  2021        PMID： 35302318      PMCID： PMC8931613          DOI： 10.3724/zdxbyxb-2021-0249

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN： 1008-9292


  55 in total

1.  Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

Authors:  Seungwon Kim; Christopher N Prichard; Maher N Younes; Yasemin D Yazici; Samar A Jasser; B Nebiyou Bekele; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

2.  Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

Authors:  Maria K Gule; Yunyun Chen; Daisuke Sano; Mitchell J Frederick; Ge Zhou; Mei Zhao; Zvonimir L Milas; Chad E Galer; Ying C Henderson; Samar A Jasser; David L Schwartz; James A Bankson; Jeffrey N Myers; Stephen Y Lai
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

3.  Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.

Authors:  Ebba Palmberg; John Inge Johnsen; Janna Paulsson; Helena Gleissman; Malin Wickström; Margareta Edgren; Arne Ostman; Per Kogner; Magnus Lindskog
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

4.  Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Authors:  Crescent R Isham; Ayoko R Bossou; Vivian Negron; Kelly E Fisher; Rakesh Kumar; Laura Marlow; Wilma L Lingle; Robert C Smallridge; Eric J Sherman; Vera J Suman; John A Copland; Keith C Bible
Journal:  Sci Transl Med       Date:  2013-01-02       Impact factor: 17.956

Review 5.  mTOR Signaling in Growth, Metabolism, and Disease.

Authors:  Robert A Saxton; David M Sabatini
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

6.  Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Authors:  Panayiotis Savvides; Govardhanan Nagaiah; Pierre Lavertu; Pingfu Fu; John J Wright; Robert Chapman; Jay Wasman; Afshin Dowlati; Scot C Remick
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

7.  Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.

Authors:  Christopher N Prichard; Seungwon Kim; Yasmin D Yazici; Dao D Doan; Samar A Jasser; Mahitosh Mandal; Jeffrey N Myers
Journal:  Laryngoscope       Date:  2007-04       Impact factor: 3.325

8.  Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.

Authors:  Christine Dierks; Jochen Seufert; Konrad Aumann; Juri Ruf; Claudius Klein; Selina Kiefer; Michael Rassner; Melanie Boerries; Andreas Zielke; Paul la Rosee; Philipp Tobias Meyer; Matthias Kroiss; Christian Weißenberger; Tilmann Schumacher; Patrick Metzger; Harald Weiss; Constantin Smaxwil; Katharina Laubner; Justus Duyster; Nikolas von Bubnoff; Cornelius Miething; Oliver Thomusch
Journal:  Thyroid       Date:  2021-04-15       Impact factor: 6.568

9.  Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.

Authors:  Sae Ishihara; Naoyoshi Onoda; Satoru Noda; Yuka Asano; Yukie Tauchi; Tamami Morisaki; Shinichiro Kashiwagi; Tsutomu Takashima; Masaichi Ohira
Journal:  Int J Oncol       Date:  2019-09-19       Impact factor: 5.650

10.  Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.

Authors:  Yina Liao; Yao Gao; An Chang; Zongjuan Li; Huayu Wang; Jing Cao; Wei Gu; Ranran Tang
Journal:  J Cell Mol Med       Date:  2020-09-15       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.